NEOGENOMICS INC
NEONext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for NEO. That does not mean none is planned.
Get an email about NEO's next catalysts
Track NEOGENOMICS (NEO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.
Website| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IO102-IO103 in combination with pembrolizumab | Phase 2 | Lung Cancer Non Small Cell | - | - |
Frequently asked questions
What is in NEOGENOMICS INC's drug pipeline?→
CatalystAlert tracks 1 drug candidate in NEOGENOMICS INC's (NEO) pipeline across Phase 2. Its lead program is IO102-IO103 in combination with pembrolizumab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NEOGENOMICS INC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for NEOGENOMICS INC (NEO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track NEO biotech catalysts?→
Add NEO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NEOGENOMICS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.